Position in LGND
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$783,027
+$214,116 QoQ
Shares Held
3,922
+30.3% QoQ
Ownership
0.020%
of shares outstanding
% of Portfolio
0.23%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in LGND Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026EntryPoint Capital, LLC holds $19,484,871 across 56 Biotechnology names. LGND ranks #2 (4.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TBPH |
Theravance Biopharma, Inc.
|
49,739 | $807,263 | |
| 2 | LGND |
Ligand Pharmaceuticals Inc
This page
|
3,922 | $783,027 | |
| 3 | ADMA |
Adma Biologics, Inc.
|
83,961 | $756,488 | |
| 4 | VCEL |
Vericel Corp
|
22,674 | $729,422 | |
| 5 | HRMY |
Harmony Biosciences Holdings, Inc.
|
24,264 | $679,634 | |
| 6 | UPB |
Upstream Bio, Inc.
|
73,568 | $662,112 | |
| 7 | INCY |
Incyte Corp
|
6,483 | $610,179 | |
| 8 | RARE |
Ultragenyx Pharmaceutical Inc.
|
26,119 | $547,193 |
All Filings in LGND
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $783,027 | 3,922 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $568,911 | 3,009 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $533,014 | 3,009 | Shares | Sole | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||